Mayne Pharma is seeking to rapidly expand its product portfolio in the US and Australia. Our business development activities are focused on prescription branded and generic products that are in late-stage development, currently approved and commercialized outside the US or Australia, or approved in the US or Australia but falling outside the license holder’s business focus. We will consider in-licensing, acquisition, co-promotion, revenue-sharing, and other partnering opportunities.
Therapeutic categories of primary interest for proprietary products include dermatology, pain management, infectious disease, women's health and urology, although we will consider other opportunities outside of these areas.
For partnering enquiries please contact us.